Publications
351
Citations
15,419
Est. group size
~50
Recurring co-author estimate
Active years
36
Publishing since 1991
Gerard Lozanski's research focuses on blood cancers, especially rare and hard-to-classify leukemias and lymphomas such as hairy cell leukemia and acute myeloid leukemia. His work combines laboratory diagnostics (including DNA methylation profiling and flow cytometry-based cell detection) with clinical studies on treatment outcomes, including studies related to COVID-19 antibody testing in blood cancer patients. This work is aimed at improving diagnosis, classification, and treatment monitoring for patients with hematologic malignancies.
Publication output has generally grown over the past decade, rising from about 11 papers in 2017 to a peak of 35 in 2023, with some year-to-year fluctuation including a dip in 2024 followed by renewed output in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant
Blood · 2026
- Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study
Clinical and Applied Thrombosis/Hemostasis · 2026
- Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
Cell stem cell · 2025
- Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study
Cancer · 2025
- 194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS
Hematological Oncology · 2025
- The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
UNC Libraries · 2025
- Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
Leukemia · 2024
- CD123 As a Therapeutic Target in Accelerated and Blast Phase Myeloproliferative Neoplasms (MPNs)
Transplantation and Cellular Therapy · 2024
- OPTIMIZATION OF A CLINICALLY VALIDATED CART FLOW ASSAY FOR COMMERCIAL ANTI-CD19 CART T-CELL THERAPY AND UNIVERSAL ASSAYS FOR DETECTION OF NOVEL CAR-T CONSTRUCTS
Cytotherapy · 2024
- Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
Cell Reports Medicine · 2023
- Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection
Vaccines · 2023
- Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
Blood Advances · 2023
- Impact of sex on outcomes in patients with hairy cell leukemia. An <scp>HCL</scp> patient data registry analysis
American Journal of Hematology · 2023
- Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
eJHaem · 2023
- DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma
Blood · 2023
- Blood×52
- Journal of Clinical Oncology×7
- Leukemia×7
- bioRxiv (Cold Spring Harbor Laboratory)×6
- Haematologica×5
- Jennifer A. Woyach
Medicine · The Ohio State University
- Kerry A. Rogers
Medicine · The Ohio State University
- Jeffrey A. Jones
Medicine · The Ohio State University
- Margaret S. Lucas
Medicine · The Ohio State University
- Jennifer A. Woyach
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile